A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

J Main; J L Brown; C Howells; R Galassini; M Crossey; P Karayiannis; P Georgiou; G Atkinson; H C Thomas

doi:10.1111/j.1365-2893.1996.tb00098.x

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

J Viral Hepat. 1996 Jul;3(4):211-5. doi: 10.1111/j.1365-2893.1996.tb00098.x.

Authors

J Main¹, J L Brown, C Howells, R Galassini, M Crossey, P Karayiannis, P Georgiou, G Atkinson, H C Thomas

Affiliation

¹ Department of Medicine, St Mary's Hospital Medical School, London, UK.

PMID: 8871884
DOI: 10.1111/j.1365-2893.1996.tb00098.x

Abstract

This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carries. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

2-Aminopurine / analogs & derivatives*
2-Aminopurine / therapeutic use
Adolescent
Adult
Antiviral Agents / therapeutic use*
Carrier State
Chronic Disease
DNA, Viral / analysis
Double-Blind Method
Famciclovir
Female
Hepatitis B / drug therapy*
Hepatitis B virus / genetics
Hepatitis B virus / physiology*
Humans
Male
Middle Aged
Virus Replication*

Substances

Antiviral Agents
DNA, Viral
2-Aminopurine
Famciclovir